H. Lundbeck A/S
HLUYY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.37B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $4.37 Billion |
|---|---|
| Enterprise Value | $11.59 Billion |
| Annual dividend | $0.20 |
| Dividend yield | 2.21% |
| Earnings per Share | $0 |
| Beta | 0.61 |
| Outstanding Shares | 198,700,000 |
Return
| Return on Equity | 14.44% |
|---|---|
| Return on Assets | 7.36% |
| Return on Invested Capital | 13.52% |
Valuation & Multiples
| P/E Ratio | 13.32 |
|---|---|
| PEG | 70.67 |
| Price to Sales | 0.17 |
| Price to Book Ratio | 0.16 |
| Enterprise Value to Revenue | 0.45 |
| Enterprise Value to EBIT | 1.98 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.81 |
| Debt to Equity | 0.35 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About H. Lundbeck A/S
5,214 employees
CEO: Charl van Zyl
H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily sp...